Evolent Health shares tumble 11% as Q2 results miss expectations

Published 07/08/2025, 21:56
 Evolent Health shares tumble 11% as Q2 results miss expectations

WASHINGTON - Evolent Health, Inc. (NYSE:EVH) shares plunged 11% after the healthcare solutions provider reported second-quarter results that fell short of analyst expectations, despite raising its full-year profitability outlook.

The company posted an adjusted loss of $0.10 per share for the second quarter, significantly missing analyst estimates of $0.08 in earnings. Revenue declined to $444.3 million from $647.1 million in the same period last year and fell short of the $459.4 million consensus forecast.

Despite the revenue miss, Evolent reported improved profitability metrics with adjusted EBITDA of $37.5 million, representing an 8.5% margin compared to 8.0% in the year-ago quarter. The company raised its full-year adjusted EBITDA guidance to a range of $140 million to $165 million.

"Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year," said Seth Blackley, Co-Founder and Chief Executive Officer. "We continue to see a rapidly accelerating pipeline for new business and based on this acceleration we would expect to exceed our historical growth rates for 2026."

For the third quarter, Evolent expects revenue between $460 million and $480 million with adjusted EBITDA of $34 million to $42 million. The company revised its full-year revenue outlook to $1.85 billion to $1.88 billion, citing "updated go-live timing for certain Performance Suite launches."

Evolent announced four new revenue agreements during the quarter, bringing its year-to-date total to 11. The company noted that "rising medical costs impacting health plans continue to drive robust demand for Evolent’s complex specialty care solutions."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.